Monitoring Plasma Voriconazole Levels May Prevent Subtheraputic Dosing in Pediatrics Hematopoeitic Stem Cell Transplantation (HCT)  by Morris, J. et al.
S188 Oral Presentationscomposed of mature, long-lived B and T-cells that do not need to be
regenerated by HSC.
Expansion of this work could enable efficient, safe transplantation
ofHSC that cannot causeGvH, resulting in a potential curative ther-
apy for almost any hematologic or immunologic disease.93
TIE21 ENDOTHELIAL CELLS MEDIATE HEMATOPOIETIC STEM CELL RE-
GENERATION VIA EGF SIGNALING
Doan, P.L.1, Russell, J.L.1, Himburg, H.A.1, Helms, K.1,
Meadows, S.K.1, Daher, P.1, Sullivan, J.M.2, Jeffords, L.B.2,
Chao, N.J.1, Kirsch, D.G.2, Chute, J.P.1 1Duke University Medical
Center, Durham, NC; 2Duke University Medical Center, Durham, NC
Hematopoietic stem cells (HSCs) reside in anatomic association
with sinusoidal vessels in the bone marrow (BM), but the mecha-
nisms through which BM endothelial cells regulate HSC regenera-
tion remain unknown. We measured the function of BM ECs in
regulating hematopoietic regeneration after ionizing radiation by
deletion of the pro-apoptotic genes, Bak and Bax, within Tie21 cells
in Tie2Cre;Bak2/2;BaxFl/- mice. Following a lethal dose of total
body irradiation (TBI), these mice demonstrated protection of BM
HSCs and 100% survival, whereas mice that retained Bax expression
in Tie21 cells demonstrated depletion of BM HSCs and only 10%
survival (p\ 0.0001). Chimeric mice which lacked Bak and Bax in
BMHSCs but retained Bak and Bax in BMECs demonstrated an in-
termediate phenotype (42% survival), indicating that the intrinsic
pathway of apoptosis regulates HSC survival from radiation in an
HSC-autonomous manner and via an EC-dependent mechanism.
To determine the mechanism through which Tie21 BM ECs
regulate HSC regeneration, we generated primary BM EC lines
from Tie2Cre;Bak2/2;BaxFl/- mice (Bax2/2 BM ECs) and
Tie2Cre;Bak2/2;BaxFl/1 control mice (Bax1/- BM ECs). BM c-
kit1sca-11lin- (KSL) stem/progenitor cells were irradiated with
300 cGy and then placed in 7 day culture with Bax2/2 BM ECs or
Bax1/- BM ECs. Culture with Bax2/2 BM ECs yielded a 2000-fold
increased number of BM KSL cells (p\0.05) compared to cultures
with Bax1/- ECs. This significant expansion of phenotypic BM stem/
progenitor cells corresponded to a 4-fold increase in CFU-S12 cells
in the Bax2/2 EC cultures vs. Bax1/- EC cultures (p 5 0.01). Inter-
estingly, following TBI, mice bearing Bak and Bax deletion in BM
ECs displayed 18-fold increased concentration of epidermal growth
factor (EGF) in BM serum compared to control mice (p5 0.04), and
inhibition of EGF signaling blocked the ability of Bax2/2BMECs to
support the expansion of BM HSCs following irradiation compared
to culture with Bax2/2 ECs alone (p5 0.0002). Moreover, the addi-
tion of EGF to Bax1/- BM ECs culture compared to culture with
Bax1/- BM ECs alone significantly increased the recovery of BM
HSCs and progenitor cells following irradiation (p5 0.0004), which
was comparable to the recovery of BM HSCs and progenitor cells
observed in Bax2/2 BM EC cultures. These data demonstrate that
therapeutic protection of the BM vascular niche protects BM
HSCs from myelotoxic injury, and this protection is mediated by
EGF action on BM HSCs.SUPPORTIVE CARE
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HIGH-DOSE WEEKLY AMBISOME ANTIFUNGAL PROPHYLAXIS IN HIGH
RISK PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANS-
PLANTATION
Mehta, P.A.1, Wallace, G.1, Davies, S.M.1, Vaughn, G.1, Kim, M.2,
Lawrence, J.1, Bleesing, J.J.1, Jodele, S.1, Marsh, R.A.1, Jordan, M.B.1,
Grimley, M.S.1, Myers, K.C.1, Kumar, A.1, Joshi, S.1, Perez, A.1,
Filipovich, A.H.1 1Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH; 2Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH
Disseminated fungal infection causes significant morbidity and
mortality in children undergoing hematopoietic cell transplantation
(HCT). The widespread use of prophylactic oral triazoles has limi-
tations of poor absorption, interindividual variability in metabolism,
and hepatic toxicity. AmBisome (Amphotericin B liposomal com-
plex) has a better safety profile than the parent drug, produces higherplasma and tissue concentrations, but long-term use is limited by the
need for frequent intravenous administration. An alternative
approach to prophylaxis is once a week (wk) high-dose AmBisome
therapy.
Both animal and adult human data suggest that this dosing sched-
ule can be effective. We have previously shown that this dosing reg-
imen led to detectable and protective plasma levels of nonliposomal
amphotericin on the seventh day in pediatric HCT patients (Mehta
et al, 2006).
Here we report our clinical experience of use of weekly high-dose
(10mg/kg) AmBisome antifungal prophylaxis in high risk pediatric
patients undergoing HCT. A total of 25 infants and children with
various hematological and immune deficiency disorders undergoing
HCT are reviewed retrospectively. The median age was 1.5 years
(range 0.25-15).None of the patients had a history of previous fungal
infection. All patients had normal renal function prior to starting
weekly AmBisome and were on cyclosporine (CSA) for graft versus
host disease prophylaxis.
Total length of therapy expanded over 7 to 54 wks (median 16
wks). Results are described in Table. Majority of the patients toler-
ated AmBisome infusion well, except rash, hypertension, increased
work of breathing and hypotension in 2, 4, 1, and 1 patient respec-
tively. Renal dysfunction (increase in Cr to twice the baseline value),
was observed in 15 patients, at a median of 9 wks (range 1-31) of ther-
apy. Of note, 2 patients sustained significant renal dysfunction, with
Cr 4.9 and 5.1 (compared to baseline of 0.8 and 0.6 respectively) at
wk 10 and 7 respectively, in the setting of septic shock and receiving
gentamicin, vancomycin and CSA. None of the patients developed
breakthrough fungal infection during weekly AmBisome therapy.
Table 1. High-Dose Weekly AmBisome Antifungal Pro-
phylaxis: Results
Number or
Observations Median (Range)Total number of patients 25
Total weeks on AmBisome 16 (7-54)
Patients with infusional reactions 5
Patients with breakthrough fungal infection 0Number of patients with renal dysfunction (increase
in Cr to $ twice the baseline value)15- Time to development of renal dysfunction (weeks) 9 (1-31)
- Number of patients with reversal of renal
dysfunction to baseline
9- baseline creatinine 0.3 (0.3-0.8)
- highest creatinine 0.8 (0.3-5.1)
- end of therapy creatinine 0.5 (0.3-1.8)* Cr - creatinine
We conclude that, high dose weekly AmBisome prophylaxis is safe
and effective and provides a simple prophylaxis regimen that can
be administered for long periods to infants and children on an
outpatient basis. This approach has been used routinely at our
institution in the past several years with continued excellent
outcomes.
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MONITORING PLASMA VORICONAZOLE LEVELS MAY PREVENT SUB-
THERAPUTIC DOSING IN PEDIATRICS HEMATOPOEITIC STEM CELL
TRANSPLANTATION (HCT)
Morris, J.1, Stewart, T.2, Bahjri, K.3, Brown, W.2, Morris, C.1 1Loma
Linda University Medical Center, Loma Linda, CA; 2Loma Linda
University Medical Center, Loma Linda, CA; 3Loma Linda University
Medical Center, Loma Linda, CA
Background: Voriconazole is frequently used for prophylaxis and
treatment of fungal infections during hematopoeitic stem cell trans-
plant (HCT). Clinical studies demonstrate a poorer outcome when
voriconazole concentrations are \ 0.5 mcg/ml. Pediatric dosing
schedules to achieve trough concentrations$ 0.5 mcg/ml are not es-
tablished and the recommended dose based on adult data is 4mg/kg/
dose q12h.
Oral Presentations S189Methods: Retrospective analysis of voriconazole trough levels in
53 pediatric patients following allogeneic HCT receiving fungal
prophylaxis with oral or IV voriconazole. Ages ranged 0.5 to 20
years, median 14 years. Serum levels were measured by high-perfor-
mance liquid chromatography. Samples were obtained 5 to 7 days
after start or change in dose of voriconazole, 298 total levels were
evaluated.
Results:The mean age of patients with levels\0.5 mcg/ml was 6.4
years and 13 years for those with levels $ 0.5mcg/ml. Most patients
failing to achieve adequate trough levels were# 9 years of age (15/17
patients). A level of$ 0.5mcg/ml was achievable in a subset of these
patients (8/15) when the dosage was increased from 4mg/kg/dose q
12h to doses ranging from 6mg to 11 mg /kg/dose q12h. 7/15 never
achieved a level$ 0.5mcg/ml despite doses ranging from 7 to 8.2mg/
kg/dose. 2/17 patients that were# 9 years of age did achieve a level$
0.5mcg/ml with dosing of 4mg/kg/dose. Changing from oral to IV
therapy in 3 patients with low trough levels did not improve the
trough level. Multi-time point measurements were $ 0.5mcg/ml at
2 to 6 hours after oral / IV dose, but fell to 0.2mcg/ml by 12 hours
in 3 patients tested. Of 298 voriconazole levels, 156 were $ 0.5
mcg/ml.
Conclusions: Unlike reports in adult patients, we found that fre-
quent monitoring of voriconazole levels was necessary in pediatric
patients less than 10 years old receiving HCT. In addition, younger
pediatric HCT patients may require more frequent dosing schedules
to achieve trough levels or initial dosing higher than the recommen-
ded adult dosing of 4mg/kg/dose q12h.96
TREATMENT OF ADENOVIRUS (ADV) INFECTIONS RESISTANT TO CIDO-
FAVIR (C) WITH CMX001 (CMX) IN PEDIATRIC PATIENTS RECEIVING
HCT
Morris, C.L.1, Painter, W.2, Lanier, R.2, Morris, J.D.1 1Loma Linda
University Hospital, Loma Linda, CA; 2Chimerix Inc, Durham, NC;
3Redlands, CA
ADV infections early after HCT are fatal in up to 50% of patients.
CDV is commonly used to treat ADV infection, but requires i.v. ad-
ministration, has renal and marrow toxicity, and virus control is vari-
able. CMX is an orally administered lipid conjugate of CDV with
decreased toxicity and increased potency against dsDNA viruses, in-
cluding ADV. We report our experience treating 4 patients with
ADV infections after HCTwith CMXwho had developed resistance
to CDV or could not tolerate CDV. All cases had GVHD prior to
onset of infection. All had positive stool pcr (2) or culture (2) 16-
64 days after HCT followed by viremia 2-11 days later. All received
CDV for 2-8 weeks before switching to CMX. ADV responded to
CDV in 2 patients followed by re-emergence after 6 weeks therapy.
Two patients had no response to CDV, one with rising viremia dur-
ing 2 weeks of treatment. Subsequent to CDV, these patients re-
ceived oral CMX at 4mg/kg twice weekly. Three had undetectable
viremia and negative GI stool pcr/cultures after 2 weeks on CMX.
One patient died of multiorgan failure due to pre-existing liver-
lung toxicity and GVHD after 4 doses of CMX. During treatment
viremia fell from 89,000 to 19,000 copy/ml. After 4-6 weeks of unde-
tectable ADV, 2 patients had CMX dose decreased to a 1x/week.
ADV was detected within 2 weeks: 1 in stool, 1 in plasma and stool.
Return to twice weekly CMX resolved infection in 1 and 1 continues
with viremia (\500 copy/ml) and GI infection. Notably, repeat PK
study in this patient showed\half of the expected levels of CMX in
plasma. ADV typing by hexon analysis was performed on samples
from plasma, stool, and biopsies. Two had subtype 31 one also
with type 5 (dual infection), two had subtype 1. Sensitivity testing
from ADV obtained at onset of infection (type 1) before treatment
with CDV and 1 obtained after 6 weeks of treatment with CDV
(type 31) showed resistance to CDV (. 100uM type 31 and 13.4
uM type 1) and CMX (both . 0.5uM). Toxicity is difficult to assess
in these complex cases but no renal or marrow toxicity was attributed
to CMX therapy. CMX 4mg/kg once weekly was not adequate to
prevent re-emergence of ADV in our two patients with C resistant
ADV. CMX can suppress, but does not appear to eradicate ADV in-
fection in severely immune compromised patients after HCT. Out-
come depends on durable pharmacologic control of both ADVinfection and GVHD that permits eventual reduction in immune
suppression.
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A COST EFFECTIVE MARKETING TOOL IN A BLOOD AND MARROW
TRANSPLANT PROGRAM
Nista, E.J. Medical University of South Carolina, Charleston, SC
Introduction: In an effort to increase communication between re-
ferring physicians and our blood and marrow transplant physicians
an e-mail marketing plan was devised using a departmental newslet-
ter. Team members provided content and the data manager format-
ted the text. Three e-mail newsletters were created and sent over
a one year period. This newsletter provided a forum for the trans-
plant physicians to discuss referral guidelines, treatment, transplant
complications, long term sequelae and recommendations, and pro-
vide links to related research and outcomes data as well as introduce
and highlight new staff members and events of interest including
newly completed clinical areas.
The newsletter was sent to two groups. The first was physicians
who had referred patients to our institution for blood and marrow
transplant. The second group was to all other oncology physicians
in South Carolina listed in theMUSCHollings Cancer Center data-
base.
Results: Physicians who had referred in the past (n5 143) averaged
a 40.3% open rate compared to non-referring physicians (n5 1242)
who had a 16.3% open rate, (the industry average for medical ser-
vices is 16.7%). Referrals tracked during the period of time the news-
letters were sent increased 48% compared to the same time the
previous year. 5.9% of these referrals were from physicians who
had not previously referred to our institution. During this same
time period six physicians who had not referred to our institution
in four years or greater referred a minimum of two patients each.
Click through rates (people who clicked on the links for additional
information and/or related websites), averaged 8.9% forMUSC’s re-
ferring physicians, non-referring physicians clicked in at 3.7%. The
industry average click through rate was 13.3%, significantly higher.
Table 1. E-Mail Run History
Open Bounce-back Click-through
Rate Rate RateIndustry Average 16.7% 5.3% 13.3%
MUSC Average to Referring Physicians 40.3% 4.2% 8.9%
MUSC Average to All Instate Oncologists 16.3% 19.2% 3.7% All data courtesy of Constant Contact.
Conclusion: The newsletter was an excellent return on investment.
It allowed the team to put their program in front of every referring,
and potential referring, physician while not taking time away from
clinical practice.
Particularly for those physicians who have referred in the past it
was an excellent and cost effective educational and marketing tool,
increasing both referrals as well as physician to physician commu-
nication. This tool used far less of the clinical staff’s time than
alternative forms of communication, (such as phone calls and
e-mails) and, (unlike conferences, in-services or physician to
physician visits), did not require any time spent away from clinical
areas.
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RELATION BETWEEN THE CIBMTR STANDARD FORMS AND THE EVOLU-
TION OF A TRANSPLANTATION CENTER DATABASE QUALITY AND FIDEL-
ITY
Filipi, C.F., Mauad, M.A., Simione, A.J., Testa, A L.H., Colturato, R
V.A., Souza, M.P., Vieira, J.O., Matedi, M.A.L.H., Meireles, F.S. Hos-
pital Amaral Carvalho, Jau, SP, Brazil
Introduction: The work of a data manager team is basically to get
the information in the patient’s chart written by physicians and lab
results to report on standard forms.
Objective:Understand and alert both physicians and data managers
that not always the clinical written routine of a Transplant Center is
